A Randomised Phase II Trial Comparing Docetaxel Plus Prednisone with Docetaxel Plus Prednisone Plus Low-Dose Cyclophosphamide in Castration-Resistant Prostate Cancer

Publisher： Karger

E-ISSN： 1421-9794|60|2|129-134

ISSN： 0009-3157

Source： Chemotherapy, Vol.60, Iss.2, 2015-02, pp. : 129-134

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Low-Dose Docetaxel Combined with Dexamethasone Is Feasible for Patients with Castration-Resistant Prostate Cancer

By  

Chemotherapy, Vol. 61, Iss. 1, 2015-0 ,pp. : 23-31

Karger

Access to resources Recommend Favorite

A Multicentre Phase II Study of Docetaxel plus Cisplatin for the Treatment of Advanced Gastric Cancer

By  

Chemotherapy, Vol. 53, Iss. 6, 2007-10 ,pp. : 454-460

Karger

Access to resources Recommend Favorite

Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer

By Amato Robert J.   Glode L. Michael   Podolnick Jeremy   Knight Robert   Crawford David  

Cancers, Vol. 3, Iss. 3, 2011-09 ,pp. : 3449-3460

MDPI

Access to resources Recommend Favorite

A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study

By  

Chemotherapy, Vol. 61, Iss. 1, 2015-0 ,pp. : 15-22

Karger

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy

By Okegawa Takatsugu   Itaya Naoshi   Hara Hidehiko   Tambo Mitsuhiro   Nutahara Kikuo  

International Journal of Molecular Sciences, Vol. 17, Iss. 12, 2016-11 ,pp. : 2008-2008

MDPI

Access to resources Recommend Favorite